Opinion channel feed – Endpoints News

Opinion channel feed

21st Century Cures Act could use a second look; It's time for the FDA to open up

9 years ago

Juno and the FDA screwed up. People died. What now?

9 years ago

Gilead needs to stop waiting and start buying; Let's embrace China as a new biopharma power

9 years ago

The longterm implications of the Trump Bump; Let’s try again on drug pricing

9 years ago

It’s Endpoints News' issue #100: The new daily biotech pub now has a little history

9 years ago

Hillary Clinton's War on Pharma II; A call for common sense reporting on Alzheimer's R&D

9 years ago

2016's drug pricing headwinds threaten a hurricane of new regulations

9 years ago

Another Ramaswamy stunt plays well on Wall Street, Martin Shkreli on shame, and more

9 years ago

Let's rethink Clinton's war on pharma; The FDA can't order the genie back into the magic lamp

9 years ago

Now that Sarepta has bolted out of the barn, the FDA wants to shut the door

9 years ago

Boehringer-Ingelheim has some explaining to do; It's time biotech came to grips with compassion

9 years ago

Thumbs Up/Thumbs Down: Major insurer delivers a bad blow to Duchenne families

9 years ago

Week in review: Clinton over Trump; the hubs have it; we'll always have Paris

9 years ago

The Endpoints poll: Clinton v Trump and widespread fretting that the FDA just blundered badly

9 years ago

Thumbs Up/Thumbs Down: The FDA damaged itself badly with the Sarepta OK

9 years ago

GSK makes a little history while outlining a familiar future

9 years ago

Senior FDA officials warned that approving $300,000 Duchenne drug will lower agency standards

9 years ago

Thumbs Up/Thumbs Down: The UN fumbles badly over access to drugs while developers think again about R&D strategies

9 years ago

Thumbs Up/Down: Brent Saunders has the right idea on drug pricing, let's support that

9 years ago

Thumbs Up/Thumbs Down: Novartis's retreat leaves plenty of casualties; Biogen orchestrates a shameful media show, and more

9 years ago

Biogen hypes a fresh set of early, upbeat results for Alzheimer’s drug

9 years ago

Thumbs Up/Thumbs Down: Amgen's silence is deafening; The drug pricing mob is back

9 years ago

Biotech has a bad day after politicos pounce on another drug pricing scandal

9 years ago

BioRegnum: The mob is back. And what's to stop them from going after the entire biopharma industry?

9 years ago

First page Previous page 6 7 8910 Next page Last page